SAN
DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel
2025 Virtual CNS Forum at 1:30 p.m. Eastern
Time on Tuesday, March 18, 2025. Chief Executive Officer
Kyle Gano and Chief Medical Officer
Eiry Roberts will present at the conference.
The live webcast can be accessed on Neurocrine Biosciences'
website under Investors at www.neurocrine.com. A replay of the
webcast will be available on the website approximately one hour
after the conclusion of the events and will be archived for
approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is
a leading neuroscience-focused, biopharmaceutical company with a
simple purpose: to relieve suffering for people with great needs.
We are dedicated to discovering and developing life-changing
treatments for patients with under-addressed neurological,
neuroendocrine and neuropsychiatric disorders. The company's
diverse portfolio includes U.S. FDA-approved treatments for tardive
dyskinesia, chorea associated with Huntington's disease, classic
congenital adrenal hyperplasia, endometriosis* and uterine
fibroids*, as well as a robust pipeline including multiple
compounds in mid- to late-phase clinical development across our
core therapeutic areas. For three decades, we have applied our
unique insight into neuroscience and the interconnections between
brain and body systems to treat complex conditions. We relentlessly
pursue medicines to ease the burden of debilitating diseases and
disorders, because you deserve brave science. For more information,
visit neurocrine.com, and follow the company on LinkedIn, X
(Formerly Twitter) and Facebook.
(*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE
SCIENCE are registered trademarks of Neurocrine Biosciences,
Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-stifel-2025-virtual-cns-forum-302398983.html
SOURCE Neurocrine Biosciences, Inc.
